Markers of Inflammation and Cardiovascular Disease Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association
Thomas A. Pearson,George A. Mensah,R. Wayne Alexander,Jeffrey L. Anderson,Richard O. Cannon,Michael H. Criqui,Yazid Y. Fadl,Stephen P. Fortmann,Yuling Hong,Gary L. Myers,Nader Rifai,Sidney C. Smith,Kathryn A. Taubert,Russell P. Tracy,Frank Vinicor +14 more
Reads0
Chats0
TLDR
There has been no consensus from professional societies or governmental agencies as to how these assays of markers of inflammation should be used in clinical practice, and a workshop to address these issues was convened in Atlanta, Ga.Abstract:
In 1998, the American Heart Association convened Prevention Conference V to examine strategies for the identification of high-risk patients who need primary prevention. Among the strategies discussed was the measurement of markers of inflammation.1 The Conference concluded that “many of these markers (including inflammatory markers) are not yet considered applicable for routine risk assessment because of: (1) lack of measurement standardization, (2) lack of consistency in epidemiological findings from prospective studies with endpoints, and (3) lack of evidence that the novel marker adds to risk prediction over and above that already achievable through the use of established risk factors.” The National Cholesterol Education Program Adult Treatment Panel III Guidelines identified these markers as emerging risk factors,1a which could be used as an optional risk factor measurement to adjust estimates of absolute risk obtained using standard risk factors. Since these publications, a large number of peer-reviewed scientific reports have been published relating inflammatory markers to cardiovascular disease (CVD). Several commercial assays for inflammatory markers have become available. As a consequence of the expanding research base and availability of assays, the number of inflammatory marker tests ordered by clinicians for CVD risk prediction has grown rapidly. Despite this, there has been no consensus from professional societies or governmental agencies as to how these assays of markers of inflammation should be used in clinical practice.
On March 14 and 15, 2002, a workshop titled “CDC/AHA Workshop on Inflammatory Markers and Cardiovascular Disease: Applications to Clinical and Public Health Practice” was convened in Atlanta, Ga, to address these issues. The goals of this workshop were to determine which of the currently available tests should be used; what results should be used to define high risk; which patients should be tested; and the indications for which the tests would be most useful. These …read more
Citations
More filters
Journal ArticleDOI
Dietary Fiber and C-Reactive Protein: Findings from National Health and Nutrition Examination Survey Data
TL;DR: It is indicated that fiber intake is independently associated with serum CRP concentration and support the recommendation of a diet with a high fiber content.
Journal ArticleDOI
Narrative Review: Assessment of C-Reactive Protein in Risk Prediction for Cardiovascular Disease
TL;DR: A framework for evaluating diagnostic tests in risk prediction is used to show what is and is not known about the role for CRP in cardiovascular risk prediction, and recommends thorough consideration of what is known about CRP's test characteristics and the effectiveness, costs, and benefits of its measurement.
Journal ArticleDOI
Impact of apoE genotype on oxidative stress, inflammation and disease risk.
TL;DR: Current information on the impact of environment (diet, exercise, smoking status, alcohol) on apoE genotype-phenotype associations are discussed with a view to identifying particular lifestyle strategies that could be adapted to counteract the 'at-risk' E4 genotype.
Journal ArticleDOI
Association between dietary fiber and markers of systemic inflammation in the Women's Health Initiative Observational Study
Yunsheng Ma,James R. Hébert,Wenjun Li,Elizabeth R. Bertone-Johnson,Barbara C. Olendzki,Sherry L. Pagoto,Lesley F. Tinker,Milagros C. Rosal,Ira S. Ockene,Judith K. Ockene,Jennifer A. Griffith,Simin Liu +11 more
TL;DR: Findings lend support to the hypothesis that a high-fiber diet is associated with lower plasma levels of IL-6 and TNF-alpha-R2.
Journal ArticleDOI
C-Reactive Protein and Reclassification of Cardiovascular Risk in the Framingham Heart Study
Peter W.F. Wilson,Michael J. Pencina,Paul F. Jacques,Jacob Selhub,Ralph B. D'Agostino,Christopher J. O'Donnell +5 more
TL;DR: Circulating levels of CRP help to estimate risk for initial cardiovascular events and may be used most effectively in persons at intermediate risk for vascular events, offering moderate improvement in reclassification of risk.
References
More filters
Journal ArticleDOI
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Scott M. Grundy,David W. Bilheimer,Alan Chait,Luther T. Clark,Margo A. Denke,Richard J. Havel,William R. Hazzard,Stephen B. Hulley,Donald B. Hunninghake,Robert A. Kreisberg,Penny M. Kris-Etherton,James M. McKenney,Michael A. Newman,Ernst J. Schaefer,Burton E. Sobel,Carolyn Somelofski,Milton C. Weinstein,H. Bryan Brewer,James I. Cleeman,Karen A. Donato,Nancy D. Ernst,Jeffrey M. Hoeg,Basil M. Rifkind,Jacques E. Rossouw,Christopher T. Sempos,Joanne M. Gallivan,Maureen N. Harris,Laurie Quint-Adler +27 more
TL;DR: Dairy therapy remains the first line of treatment of high blood cholesterol, and drug therapy is reserved for patients who are considered to be at high risk for CHD, and the fundamental approach to treatment is comparable.
Journal ArticleDOI
Atherosclerosis — An Inflammatory Disease
TL;DR: Atherosclerosis is an inflammatory disease as discussed by the authors, and it is a major cause of death in the United States, Europe, and much of Asia, despite changes in lifestyle and use of new pharmacologic approaches to lower plasma cholesterol concentrations.
Journal ArticleDOI
Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women
Stephen B. Hulley,Deborah Grady,Trudy L. Bush,Curt D Furberg,David M. Herrington,Betty Riggs,Eric Vittinghoff +6 more
TL;DR: Treatment with oral conjugated equine estrogen plus medroxyprogesterone acetate did not reduce the overall rate of CHD events in postmenopausal women with established coronary disease and the treatment did increase the rate of thromboembolic events and gallbladder disease.
Journal ArticleDOI
C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women
TL;DR: The addition of the measurement of C-reactive protein to screening based on lipid levels may provide an improved method of identifying persons at risk for cardiovascular events.
Related Papers (5)
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Scott M. Grundy,David W. Bilheimer,Alan Chait,Luther T. Clark,Margo A. Denke,Richard J. Havel,William R. Hazzard,Stephen B. Hulley,Donald B. Hunninghake,Robert A. Kreisberg,Penny M. Kris-Etherton,James M. McKenney,Michael A. Newman,Ernst J. Schaefer,Burton E. Sobel,Carolyn Somelofski,Milton C. Weinstein,H. Bryan Brewer,James I. Cleeman,Karen A. Donato,Nancy D. Ernst,Jeffrey M. Hoeg,Basil M. Rifkind,Jacques E. Rossouw,Christopher T. Sempos,Joanne M. Gallivan,Maureen N. Harris,Laurie Quint-Adler +27 more